Induction of erythropoiesis using human vascular networks genetically engineered for controlled erythropoietin release

Blood

Volumn 118, Issue 20, 2011, Pages 5420-5428

  Lin, Ruei Zeng ^a   Dreyzin, Alexandra ^a   Aamodt, Kristie ^a   Li, Dan ^a   Jaminet, Shou Ching S ^a   Dudley, Andrew C ^b   Melero Martin, Juan M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOODSTREAM INFECTION; ENDOTHELIAL COLONY FORMING CELL; ENDOTHELIUM CELL; ERYTHROPOIESIS; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULARIZATION;

EID: 81555214653     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-372946     Document Type: Article

References (40)

1. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21-39.
2. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004;22(11):1393-1398. (Pubitemid 39482858)
3. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med. 1987;316(2):73-78. (Pubitemid 17052741)
4. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139(2):137-147.
5. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int. 2003;64(1):295-304. (Pubitemid 36714184)
6. Coladonato JA, Frankenfield DL, Reddan DN, et al. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol. 2002;13(5):1288-1295. (Pubitemid 34441410)
7. Anderson WF. Prospects for human gene therapy. Science. 1984;226(4673):401-409. (Pubitemid 14012809)
8. Friedmann T. A brief history of gene therapy. Nat Genet. 1992;2(2):93-98.
9. Joki T, Machluf M, Atala A, et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol. 2001;19(1):35-39. (Pubitemid 32051953)
10. Read TA, Sorensen DR, Mahesparan R, et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol. 2001;19(1):29-34. (Pubitemid 32054367)
11. Kunugiza Y, Tomita N, Taniyama Y, et al. Acceleration of wound healing by combined gene transfer of hepatocyte growth factor and prostacyclin synthase with Shima Jet. Gene Ther. 2006;13(5):1143-1152. (Pubitemid 44084073)
12. Deodato B, Arsic N, Zentilin L, et al. Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Ther. 2002;9(12):777-785. (Pubitemid 34679305)
13. Sheridan C. Gene therapy finds its niche. Nat Biotechnol. 2011;29(2):121-128.
14. Sánchez-Martín D, Sanz L, Alvarez-Vallina L. Engineering human cells for in vivo secretion of antibody and nonantibody therapeutic proteins. [published online ahead of print March 22, 2011] Curr Opin Biotechnol. doi: 10.1016/j.copbio.2011.03.001
15. Au P, Tam J, Fukumura D, Jain RK. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood. 2008;111(9):4551-4558.
16. Traktuev DO, Prater DN, Merfeld-Clauss S, et al. Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. Circ Res. 2009;104(12):1410-1420.
17. Schechner JS, Nath AK, Zheng L, et al. In vivo formation of complex microvessels lined by human endothelial cells in an immunodeficient mouse. Proc Natl Acad Sci U S A. 2000;97(16):9191-9196. (Pubitemid 30626696)
18. Melero-Martin JM, Khan ZA, Picard A, Wu X, Paruchuri S, Bischoff J. In vivo vasculogenic potential of human blood-derived endothelial progenitor cells. Blood. 2007;109(11):4761-4768. (Pubitemid 46827769)
19. Melero-Martin JM, Kang S-Y, Khan ZA, Yuan L, Oettgen P, Bischoff J. Engineering robust and functional vascular networks in vivo with human adult and cord blood-derived progenitor cells. Circ Res. 2008;103(2):194-202.
20. Lin RZ, Dreyzin A, Aamodt K, Dudley AC, Melero-Martin JM. Functional endothelial progenitor cells from cryopreserved umbilical cord blood. Cell Transplant. 2011;20:515-522.
21. Shih SC, Smith LE. Quantitative multi-gene transcriptional profiling using real-time PCR with a master template. Exp Mol Pathol. 2005;79(1):14-22. (Pubitemid 40984747)
22. Chong ZZ, Kang J-Q, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation. 2002;106(23):2973-2979. (Pubitemid 35424751)
23. Carlini RG, Alonzo EJ, Dominguez J, et al. Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int. 1999;55(2):546-553. (Pubitemid 29082880)
24. Chen X, Aledia AS, Popson SA, Him LK, Hughes CCW, George S. Rapid anastomosis of endothelial precursor cell-derived vessels with host vasculature is promoted by a high density of cotransplanted fibroblasts. Tissue Eng Part A. 2010;16(2):585-594.
25. Hamamori Y, Samal B, Tian J, Kedes L. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure. J Clin Invest. 1995;95(4):1808-1813.
26. Johnson HA, Vera Roman JM. Compensatory renal enlargement. Hypertrophy versus hyperplasia. Am J Pathol. 1966;49(1):1-13.
27. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000;105(1):71-77. (Pubitemid 30036389)
28. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood. 2004;104(9):2752-2760. (Pubitemid 39434958)
29. Eliopoulos N, Al-Khaldi A, Crosato M, Lachapelle K, Galipeau J. A neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent mice. Gene Ther. 2003;10(6):478-489. (Pubitemid 36395265)
30. Régulier E, Schneider BL, Deglon N, Beuzard Y, Aebischer P. Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. Gene Ther. 1998;5(8):1014-1022. (Pubitemid 28401302)
31. Naffakh N, Pinset C, Montarras D, et al. Long-term secretion of therapeutic proteins from genetically modified skeletal muscles. Hum Gene Ther. 1996;7(1):11-21. (Pubitemid 26119479)
32. Lejnieks DV, Ramesh N, Lau S, Osborne WR. Stomach implant for long-term erythropoietin expression in rats. Blood. 1998;92(3):888-893. (Pubitemid 28355471)
33. Bachoud-Lévi AC, Deglon N, Nguyen JP, et al. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther. 2000;11(12):1723-1729.
34. Hortelano G, Al-Hendy A, Ofosu FA, Chang PL. Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood. 1996;87(12):5095-5103. (Pubitemid 26189850)
35. Orive G, Hernández RM, Gascón AR, et al. Cell encapsulation: promise and progress. Nat Med. 2003;9(1):104-107. (Pubitemid 36098269)
36. de Vos P, Marchetti P. Encapsulation of pancreatic islets for transplantation in diabetes: the untouchable islets. Trends Mol Med. 2002;8(8):363-366. (Pubitemid 34826718)
37. Alvarez-Vallina L, Sanz L. The therapeutic potential of engineered human neovessels for cellbased gene therapy. Expert Opin Biol Ther. 2011;11(1):67-76.
38. Compte M, Alonso-Camino V, Santos-Valle P, et al. Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system. Gene Ther. 2010;17(6):745-751.
39. Kaushal S, Amiel GE, Guleserian KJ, et al. Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nat Med. 2001;7(9):1035-1040. (Pubitemid 32937384)
40. Huang L, Hou D, Thompson MA, et al. Acute myocardial infarction in swine rapidly and selectively releases highly proliferative endothelial colony forming cells (ECFCs) into circulation. Cell Transplant. 2007;16(9):887-897. (Pubitemid 351448606)